Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-04-14
Schrödinger, Inc.
Schrödinger sells computational chemistry and discovery workflow software to life sciences customers and also uses its platform in partnered and proprietary drug programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Depth, With Option-Rich Upside
The rerating case is a cleaner software-led discovery operating system with funded pipeline optionality, not a binary biotech jackpot. If hosted contracts preserve ACV growth and partnerships absorb later-stage spend, upside is meaningful but bounded.

Analysis

Thesis
Schrödinger can create solid 5-year equity upside if it turns embedded discovery software into a cleaner hosted workflow system with durable ACV growth, adds higher-value modules like predictive toxicology, and externalizes most clinical spend through partners so pipeline upside remains option value rather than a balance-sheet drag.
Last Economy Alignment
Cheaper compute and better models make simulation-led drug discovery more useful, and Schrödinger owns a real workflow control point in LiveDesign. It is not pivotal infrastructure, though, and parts of the modeling stack still face internalization and commoditization risk.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.6x (from 5 most recent analyses)
Reasoning
The upside is mainly a business-mix cleanup, not a moonshot drug jackpot. If hosted contracts make software demand more visible, new modules expand wallet share, and partnered assets preserve royalty optionality without reopening heavy burn, the market can value Schrödinger more like a cleaner scientific software company with biotech upside attached. The ceiling stays bounded because clinical proof, pharma sales cycles, and internal tool substitution still matter.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof transfer. Schrödinger must prove that embedded workflow ownership can keep pricing power as AI tools get cheaper, that the hosted transition improves visibility without masking weak demand, and that clinical assets are validated or partnered before they become a recurring cash drag. The stock works best if software and option value reinforce each other; it struggles if software stays merely helpful and therapeutics remain unproven.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.55
They sit inside the daily workflow where drug teams organize data, run simulations, and increasingly call outside AI tools, which gives them a useful control point as compute gets cheaper. The risk is that big pharma rebuilds enough of this stack internally and turns the company into a replaceable modeling layer.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$21.13
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case